ArticleFrontiers in oncology2025
A large-scale study integrating CEA and tumor deposits to evaluate prognosis in colon cancer patients.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Reliable prediction of long-term survival in colon cancer remains limited by staging system constraints. CEA and tumor deposits (TD) are known prognostic markers, but their combined predictive value is underexplored. Materials and Methods: We retrospectively analyzed 1, 029 patients with locally advanced colon cancer who underwent radical resection. A CEA-TD scoring system was developed and integrated with key clinicopathologic variables to construct a prognostic nomogram. Results: Both TD(+) and elevated CEA levels were independently associated with significantly worse overall survival (HR for TD = 1.985, CEA = 2.209; all P < 0.01). The CEA-TD score effectively stratified patients into four risk categories, each with distinct survival outcomes (P < 0.001). The final nomogram, incorporating CEA-TD score, T stage, N stage, grade, and tumor location, demonstrated high predictive performance, with AUCs of 0.796, 0.834, and 0.807 for 1-, 3-, and 5-year OS in the training cohort, and comparable values in internal and external validations. The C-index reached 0.800, outperforming traditional prognostic factors. Kaplan-Meier and risk curve analyses confirmed the model's discriminative capacity. Conclusions: The CEA-TD-based nomogram offers accurate, clinically applicable risk stratification for LOCC patients, supporting personalized treatment strategies and improved prognostic assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.